Fertility Preservation Iatrogenic denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for FERTILITY PRESERVATION IATROGENIC are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Iatrogenic Fertility Preservation as Experimental — and Why That Classification Is Often Incorrect

Fertility preservation before gonadotoxic medical treatment — including oocyte cryopreservation, sperm banking, and embryo cryopreservation — has been recognized as standard of care by major reproductive medicine and oncology professional societies for well over a decade. When Aetna denies these services as "experimental, investigational, or unproven," it is applying a classification that contradicts the current scientific and medical consensus. This is one of the most successfully appealed denial types in the fertility-preservation context.

## Why This Denial Is Appealable

Aetna's own clinical policy bulletins are periodically updated to reflect the evolving standard of care; in many cases the policy already recognizes oocyte and embryo cryopreservation as non-experimental for patients facing gonadotoxic treatment. If the denial was issued in error against a policy that already covers the service, it should overturn immediately on internal review. If Aetna's policy genuinely lags behind professional consensus, the external review process exists specifically to address this gap — IROs apply independent medical judgment and frequently overturn denials where insurer policy has not kept pace with accepted practice.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or applicable state law, you are entitled to a full-and-fair internal review. File within the EOB deadline — typically 180 days. Some states have enacted fertility-preservation mandates that independently require coverage and should be raised in the appeal.
• External review: Under ACA §2719, binding independent external review is available after exhausting internal remedies. Total window approximately four months. Expedited external review (72-hour decision) is critically important here: if the underlying cancer treatment cannot safely be delayed, you qualify for expedited review and should request it explicitly and in writing.

## Concrete Appeal Steps and Timeline

1. Pull Aetna's current clinical policy bulletin for the CPT codes billed — confirm whether the policy itself already recognizes the service as non-experimental. 2. Obtain an oncologist or treating physician letter documenting that gonadotoxic treatment is planned, the urgency timeline, and that fertility preservation is medically indicated and consistent with standard of care. 3. Request expedited internal appeal and expedited external review simultaneously, given the treatment timeline. 4. Gather professional society position statements from the relevant organizations (e.g., ASRM, ASCO) — cite by organization name only.

## Documentation to Gather

• Treating physician/oncologist letter: Confirms the planned gonadotoxic treatment, the expected impact on reproductive function, the urgency of the timeline, and that fertility preservation is standard-of-care for this clinical situation.
• Aetna's current policy bulletin: Highlight any language already recognizing the service as standard care. If the policy has been updated since the denial, attach both versions.
• Professional society position statements: ASRM, ASCO, and other relevant bodies have published formal position statements supporting fertility preservation before gonadotoxic treatment. Attach the most current versions.
• Pathology and staging records: Confirm the underlying diagnosis and treatment plan.
• State mandate documentation: If your state has a fertility-preservation insurance mandate, cite the applicable statute.

## Criteria-Mapping Structure

In your appeal letter, reproduce the experimental/investigational criteria from Aetna's policy. For each criterion (e.g., sufficient evidence in peer-reviewed literature, endorsement by professional societies, use outside a research protocol), document the specific evidence that satisfies it. Present the professional society endorsements by organization name. A criterion-by-criterion rebuttal is far more difficult to uphold than a policy that simply asserts the service is experimental without addressing the current evidence base.